Basilea reports strong 2024 full-year results

Swiss drug developer Basilea Pharmaceutica (SIX: BSLN) yesterday announced its results for the financial year ended December 31, 2024.

For the full year 2024, Basilea recognized total revenue of 208.5 million francs ($18.6 million), versus 157.6 million francs in 2023. This included royalty income of 96.7 million francs.

Basilea recorded an operating profit of 61.2 million francs (versus 19.2 million francs in 2023). As a consequence of its sustained profitability and its positive mid-term financial outlook, the company recognized deferred tax assets of 17.3 million francs, which led to a net profit of 77.6 million francs (10.5 million francs in 2023), resulting in basic and diluted earnings per share of 6.42 francs and 5.83 francs, respectively.